University of Chicago and AbbVie Extend Cancer Research Partnership Through 2027
Key Insights
The University of Chicago Medicine (search) and AbbVie (search) have extended their cancer (search) research collaboration through 2027, building on a partnership that began in 2016.
The extension aims to accelerate medical research in oncology and streamline clinical trials operations to improve connectivity between clinicians and researchers.
The collaboration will benefit from enhanced infrastructure with the planned opening of the AbbVie (search) Foundation Cancer (search) Pavilion in 2027, Illinois' first freestanding cancer center.
The University of Chicago Medicine (search) has announced an extended collaboration agreement with AbbVie (search) through 2027 to support innovative solutions in cancer (search) research and clinical trials. Building on a partnership that began in 2016, this extension marks more than a decade of collaboration focused on translational and clinical research to improve and accelerate positive outcomes for patients with cancer.
Despite significant advances in cancer (search) treatment, the disease remains a leading cause of death worldwide, underscoring the critical need for continued innovation in therapeutic approaches and clinical trial methodologies. This extended partnership positions both organizations to address these challenges through collaborative research and accelerated translation of discoveries to patient care.
Partnership Focus and Objectives
"The AbbVie-UChicago Medicine collaboration has created valuable opportunities for deep and meaningful scientific discussion and the development of clinical trials for cancer (search) treatment," said Kunle Odunsi, MD, PhD, Director of the University of Chicago Medicine Comprehensive Cancer Center (search) and AbbVie (search) Foundation Distinguished Professor. "This partnership is an exceptional model of industry and academia working together with a patient-centered focus. Our ambition is that this clinical and translational collaboration continues to positively impact public health and advance cancer treatment."
The extension of the collaboration is designed to further accelerate and advance medical research in oncology and streamline clinical trials operations to provide greater connectivity between clinicians and researchers at both organizations.
Infrastructure Enhancement
This collaboration will benefit from enhanced infrastructure as UChicago Medicine prepares to open the AbbVie (search) Foundation Cancer (search) Pavilion in 2027, Illinois' first freestanding cancer center with dedicated clinical trial spaces and state-of-the-art research facilities.
Industry Perspective
"Our partnership with the University of Chicago is driven by our shared dedication to advancing cancer (search) research and clinical innovation," said Andrew Souers, PhD, vice president, oncology discovery research at AbbVie (search). "While we have made significant progress in cancer research, there is more to accomplish together. We look forward to deepening our long-standing collaboration to continue delivering meaningful, lasting impact for people living with cancer."